Neurodawn Pharmaceutical Co., Ltd.
15
5
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
20%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Y-4 to Treat the Postherpetic Neuralgia
Role: lead
A Phase 1 Study of Y-3 in US Healthy Volunteers.
Role: lead
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
Role: lead
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
Role: lead
Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
Role: lead
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
Role: collaborator
To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Role: collaborator
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
Role: collaborator
Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Role: collaborator
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
Role: collaborator
Y-3 for Injection in the Treatment of Acute Ischemic Stroke
Role: collaborator
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
Role: collaborator
EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
Role: collaborator
Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
Role: collaborator
Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
Role: collaborator
All 15 trials loaded